Bank of New York Mellon Corp grew its stake in Arvinas Inc (NASDAQ:ARVN) by 32.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission

Were Hedge Funds Right About HNI Corp (HNI)?

02:04pm, Saturday, 18'th Apr 2020
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Alliancebernstein L.P. boosted its position in shares of Arvinas Inc (NASDAQ:ARVN) by 38.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Arvinas Inc (NASDAQ:ARVN) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,680,000 shares, a growth of 16.9% from the
Cantor Fitzgerald reiterated their buy rating on shares of Arvinas (NASDAQ:ARVN) in a report published on Tuesday, TipRanks reports. Cantor Fitzgerald currently has a $75.00 price target on the stock.
Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic
NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
UBS Group AG trimmed its stake in shares of Arvinas Inc (NASDAQ:ARVN) by 23.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commis
Franklin Resources Inc. purchased a new stake in shares of Arvinas Inc (NASDAQ:ARVN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purch
Goldman Sachs Group Inc. lifted its position in shares of Arvinas Inc (NASDAQ:ARVN) by 105.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exch
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE